<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03021291</url>
  </required_header>
  <id_info>
    <org_study_id>GS-100-009</org_study_id>
    <nct_id>NCT03021291</nct_id>
  </id_info>
  <brief_title>Extension Study of Gelesis100 on Body Weight</brief_title>
  <acronym>GLOW-EX</acronym>
  <official_title>An Open-label Study Assessing the Effect of Gelesis100 on Weight Loss and Weight Maintenance in Overweight and Obese Subjects Who Completed the GLOW Study (G-04)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gelesis, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gelesis, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to assess the effect of Gelesis100 on body weight after an additional
      exposure of 24 weeks in subjects who completed the 24-week treatment period, and had at least
      3% weight loss, in the Gelesis Loss Of Weight GLOW, NCT02307279) study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 25, 2017</start_date>
  <completion_date type="Actual">December 15, 2017</completion_date>
  <primary_completion_date type="Actual">December 8, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in body weight</measure>
    <time_frame>Measured at baselines of the GLOW and GLOW-EX study (day 197) and day 339</time_frame>
    <description>Percent (%) change from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Body weight responders (5%)</measure>
    <time_frame>Measured at baselines of the GLOW and GLOW-EX study (day 197) and day 339</time_frame>
    <description>Change from baseline in body weight of at least 5%</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in plasma glucose status (normal, impaired, diabetic)</measure>
    <time_frame>Measured at baselines of the GLOW and GLOW-EX study (day 197) and day 339</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plasma glucose</measure>
    <time_frame>Measured at baselines of the GLOW and GLOW-EX study (day 197) and day 339</time_frame>
    <description>Change from baseline in millimoles per liter (mmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in insulin resistance</measure>
    <time_frame>Measured at baselines of the GLOW and GLOW-EX study (day 197) and day 339</time_frame>
    <description>Change from baseline in homeostatic model assessment of insulin resistance (HOMA-IR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in glycosylated hemoglobin (HbA1c)</measure>
    <time_frame>Measured at baselines of the GLOW and GLOW-EX study (day 197) and day 339</time_frame>
    <description>Change from baseline (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in body mass index (BMI)</measure>
    <time_frame>Measured at baselines of the GLOW and GLOW-EX study (day 197) and day 339</time_frame>
    <description>Measured as body weight in kilograms divided by height in meters-squared (kg/m2)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Body weight responders (10%)</measure>
    <time_frame>Measured at baselines of the GLOW and GLOW-EX study (day 197) and day 339</time_frame>
    <description>Change from baseline in body weight of at least 10%</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in excess body weight</measure>
    <time_frame>Measured at baselines of the GLOW and GLOW-EX study (day 197) and day 339</time_frame>
    <description>Change from baseline (%)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in body weight status (normal, overweight, obese)</measure>
    <time_frame>Measured at baselines of the GLOW and GLOW-EX study (day 197) and day 339</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in waist circumference</measure>
    <time_frame>Measured at baselines of the GLOW and GLOW-EX study (day 197) and day 339</time_frame>
    <description>Change from baseline in waist circumference (centimeters)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in serum insulin</measure>
    <time_frame>Measured at baselines of the GLOW and GLOW-EX study (day 197) and day 339</time_frame>
    <description>Change from baseline in milliunits per liter (mU/L)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in serum C-reactive protein (CRP)</measure>
    <time_frame>Measured at baselines of the GLOW and GLOW-EX study (day 197) and day 339</time_frame>
    <description>Measured in milligrams per liter (mg/L)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in total cholesterol, serum low-density lipoprotein (LDL), high-density lipoprotein (HDL), total cholesterol/HDL ratio, and triglycerides</measure>
    <time_frame>Measured at baselines of the GLOW and GLOW-EX study (day 197) and day 339</time_frame>
    <description>measured in milligrams per deciliter (mg/dL)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change vital signs: heart rate, supine and standing systolic and diastolic blood pressure (SBP, DBP)</measure>
    <time_frame>Measured at baselines of the GLOW and GLOW-EX study (day 197) and day 339</time_frame>
    <description>Measured in beats per minute (heart rate) or millimeters of mercury (mmHg) for blood pressure</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in food intake</measure>
    <time_frame>Measured at baselines of the GLOW and GLOW-EX study (day 197) and day 339</time_frame>
    <description>Assessed by 24 hr dietary recall</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Impact of Weight on Quality Of Life (IWQOL)</measure>
    <time_frame>Measured at baselines of the GLOW and GLOW-EX study (day 197) and day 339</time_frame>
    <description>Change in global and individual questionnaire subscale scores</description>
  </other_outcome>
  <other_outcome>
    <measure>All adverse events (AE), serious adverse events (SAE), and gastrointestinal symptoms</measure>
    <time_frame>Measured at baselines of the GLOW and GLOW-EX study (day 197) and day 339</time_frame>
    <description>Number and % of subjects with AE/SAEs spontaneously reported; gastrointestinal symptoms solicited via questionnaire.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in serum sodium</measure>
    <time_frame>Measured at baselines of the GLOW and GLOW-EX study (day 197) and day 339</time_frame>
    <description>Change from baseline in millimoles per liter (mmol/L)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in serum potassium</measure>
    <time_frame>Measured at baselines of the GLOW and GLOW-EX study (day 197) and day 339</time_frame>
    <description>Change from baseline (mmol/L)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in serum chloride</measure>
    <time_frame>Measured at baselines of the GLOW and GLOW-EX study (day 197) and day 339</time_frame>
    <description>Change from baseline (mmol/L)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in serum calcium</measure>
    <time_frame>Measured at baselines of the GLOW and GLOW-EX study (day 197) and day 339</time_frame>
    <description>Change from baseline (mmol/L)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in serum magnesium</measure>
    <time_frame>Measured at baselines of the GLOW and GLOW-EX study (day 197) and day 339</time_frame>
    <description>Change from baseline (mmol/L)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in serum phosphorus</measure>
    <time_frame>Measured at baselines of the GLOW and GLOW-EX study (day 197) and day 339</time_frame>
    <description>Change from baseline (mmol/L)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in serum glucose</measure>
    <time_frame>Measured at baselines of the GLOW and GLOW-EX study (day 197) and day 339</time_frame>
    <description>Change from baseline (mmol/L)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in blood urea nitrogen (BUN)</measure>
    <time_frame>Measured at baselines of the GLOW and GLOW-EX study (day 197) and day 339</time_frame>
    <description>Change from baseline (mmol/L)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in serum creatinine</measure>
    <time_frame>Measured at baselines of the GLOW and GLOW-EX study (day 197) and day 339</time_frame>
    <description>Change from baseline in micromoles per liter (umol/L)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in serum uric acid</measure>
    <time_frame>Measured at baselines of the GLOW and GLOW-EX study (day 197) and day 339</time_frame>
    <description>Change from baseline (umol/L)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in total bilirubin</measure>
    <time_frame>Measured at baselines of the GLOW and GLOW-EX study (day 197) and day 339</time_frame>
    <description>Change from baseline (umol/L)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in alanine aminotransferase (ALT)</measure>
    <time_frame>Measured at baselines of the GLOW and GLOW-EX study (day 197) and day 339</time_frame>
    <description>Change from baseline in international units per liter (IU/L)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in aspartate transaminase (AST)</measure>
    <time_frame>Measured at baselines of the GLOW and GLOW-EX study (day 197) and day 339</time_frame>
    <description>Change from baseline (IU/L)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in gamma-glutamyl transpeptidase (GGT)</measure>
    <time_frame>Measured at baselines of the GLOW and GLOW-EX study (day 197) and day 339</time_frame>
    <description>Change from baseline (IU/L)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in alkaline phosphatase (ALP)</measure>
    <time_frame>Measured at baselines of the GLOW and GLOW-EX study (day 197) and day 339</time_frame>
    <description>Change from baseline (IU/L)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in serum total protein</measure>
    <time_frame>Measured at baselines of the GLOW and GLOW-EX study (day 197) and day 339</time_frame>
    <description>Change from baseline (g/L)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in serum albumin</measure>
    <time_frame>Measured at baselines of the GLOW and GLOW-EX study (day 197) and day 339</time_frame>
    <description>Change from baseline (g/L)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in hematocrit</measure>
    <time_frame>Measured at baselines of the GLOW and GLOW-EX study (day 197) and day 339</time_frame>
    <description>Change from baseline (%)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in hemoglobin</measure>
    <time_frame>Measured at baselines of the GLOW and GLOW-EX study (day 197) and day 339</time_frame>
    <description>Change from baseline (mmol/L)</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Overweight and Obesity</condition>
  <arm_group>
    <arm_group_label>Gelesis100</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gelesis100 (2.25 g) twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Gelesis100 (2.25 g)</intervention_name>
    <description>Three capsules of Gelesis100, each containing a 750 mg mixture of two food-grade materials: carboxymethylcellulose that is cross-linked with citric acid.</description>
    <arm_group_label>Gelesis100</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Completion of the GLOW study with at least 3% weight loss

          2. Informed Consent Form signed by the subjects at the end of the GLOW study

        Exclusion Criteria:

          1. Pregnancy (or positive serum or urine pregnancy test(s) in females of childbearing
             potential) or lactation

          2. Absence of medically approved contraceptive methods in females of childbearing
             potential (e.g., hysterectomy, non-oral contraceptive medications or intrauterine
             device combined with a barrier method, two combined barrier methods such as diaphragm
             and condom or spermicide, or condom and spermicide; bilateral tubal ligation and
             vasectomy are not acceptable contraceptive methods)

          3. Subjects considering smoking cessation during the study

          4. Subjects anticipating surgical intervention during the study

          5. Significant intolerance to the study product during the GLOW study

          6. Increase of ≥ 0.5% point (≥ 5.5 mmol/mol) in HbA1c from the Baseline Visit of the GLOW
             study in subjects with treated or untreated type 2 diabetes if considered clinically
             relevant, or any increase if HbA1c is &gt; 8.5% (&gt; 69 mmol/mol)

          7. Increase of ≥ 10% in total cholesterol, low-density lipoprotein (LDL) cholesterol, or
             triglycerides from the Baseline Visit of the GLOW study in subjects with elevated
             lipids at the Baseline Visit of the GLOW study if considered clinically relevant, or
             any increase if serum LDL cholesterol is ≥ 190 mg/dL (≥ 4.93 mmol/L) and/or serum
             triglycerides are ≥ 500 mg/dL (≥ 5.65 mmol/L)

          8. Increase of ≥ 10 mm Hg in supine systolic blood pressure (SBP) and/or supine diastolic
             blood pressure (DBP) from the Baseline Visit of the GLOW study in subjects with
             treated or untreated hypertension if considered clinically relevant, or any increase
             if supine SBP is &gt; 160 mm Hg and/or supine DBP is &gt; 95 mm Hg, based on the mean of two
             consecutive readings

          9. Poor subject compliance with the GLOW study procedures and recommendations and/or
             major protocol deviation

         10. Anticipated requirement for use of prohibited concomitant medications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hassan Heshmati, MD</last_name>
    <role>Study Director</role>
    <affiliation>Gelesis, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arternis Institute for Clinical Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Investigators</name>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <zip>92780</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westside Center for Clinical Research</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pennington Biomedical Research</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston University Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cornell Weill Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aventiv Research</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Geisinger Health System</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Diabetes and Endocrinology</name>
      <address>
        <city>Round Rock</city>
        <state>Texas</state>
        <zip>78681</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health &amp; Care SRO</name>
      <address>
        <city>Prague</city>
        <zip>182 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cophenhagen</name>
      <address>
        <city>Copenhagen</city>
        <zip>DK-1958</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Policlinico San Donato</name>
      <address>
        <city>Milan</city>
        <zip>20097</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rome</name>
      <address>
        <city>Rome</city>
        <zip>00186</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Navarra</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 12, 2017</study_first_submitted>
  <study_first_submitted_qc>January 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2017</study_first_posted>
  <last_update_submitted>February 15, 2018</last_update_submitted>
  <last_update_submitted_qc>February 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

